BRPI0923544A2 - anticorpo anti-idiótipos contra um anticorpo contra o peptídeo beta amiloide - Google Patents
anticorpo anti-idiótipos contra um anticorpo contra o peptídeo beta amiloideInfo
- Publication number
- BRPI0923544A2 BRPI0923544A2 BRPI0923544A BRPI0923544A BRPI0923544A2 BR PI0923544 A2 BRPI0923544 A2 BR PI0923544A2 BR PI0923544 A BRPI0923544 A BR PI0923544A BR PI0923544 A BRPI0923544 A BR PI0923544A BR PI0923544 A2 BRPI0923544 A2 BR PI0923544A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody against
- amyloid beta
- beta peptide
- idiotype
- idiotype antibody
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 230000003302 anti-idiotype Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08022235.9 | 2008-12-22 | ||
EP08022235 | 2008-12-22 | ||
PCT/EP2009/009160 WO2010072384A1 (en) | 2008-12-22 | 2009-12-18 | ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0923544A2 true BRPI0923544A2 (pt) | 2016-01-26 |
BRPI0923544B1 BRPI0923544B1 (pt) | 2021-11-23 |
Family
ID=40581970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0923544-2A BRPI0923544B1 (pt) | 2008-12-22 | 2009-12-18 | Uso de um anticorpo anti-idiótipo da linhagem celular dsm acc2939 e método para a determinação imunológica de um anticorpo contra o peptídeo beta amiloide em uma amostra |
Country Status (22)
Country | Link |
---|---|
US (2) | US8614297B2 (pt) |
EP (1) | EP2379601B1 (pt) |
JP (1) | JP5642702B2 (pt) |
KR (2) | KR101777899B1 (pt) |
CN (2) | CN102257010A (pt) |
AR (1) | AR074816A1 (pt) |
AU (1) | AU2009331900A1 (pt) |
BR (1) | BRPI0923544B1 (pt) |
CA (1) | CA2746779C (pt) |
CY (1) | CY1118420T1 (pt) |
DK (1) | DK2379601T3 (pt) |
ES (1) | ES2595981T3 (pt) |
HR (1) | HRP20161398T1 (pt) |
HU (1) | HUE030478T2 (pt) |
IL (1) | IL213343A0 (pt) |
LT (1) | LT2379601T (pt) |
MX (2) | MX2011006641A (pt) |
PL (1) | PL2379601T3 (pt) |
PT (1) | PT2379601T (pt) |
SI (1) | SI2379601T1 (pt) |
TW (1) | TWI424162B (pt) |
WO (1) | WO2010072384A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
TW201348247A (zh) * | 2012-05-21 | 2013-12-01 | Abbvie Inc | 利用蛋白質a親和性層析之非人類抗體之新穎純化 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3176580A1 (en) * | 2015-12-01 | 2017-06-07 | Roche Diagnostics GmbH | Method for reduction of interferences in immunoassays |
AU2017321642A1 (en) * | 2016-08-31 | 2019-04-11 | Eiken Kagaku Kabusiki Kaisha | Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219730A (en) | 1982-09-28 | 1993-06-15 | New York University | Idiotype-anti-idiotype immunoassay |
US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
EP0170302A1 (fr) | 1984-06-27 | 1986-02-05 | l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire | Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
WO1987002778A1 (en) | 1985-10-22 | 1987-05-07 | Cooper-Lipotech | Solid-phase liposome immunoassay system |
US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
WO1990005301A1 (en) | 1988-11-03 | 1990-05-17 | Igen, Inc. | Electrochemiluminescent assays |
WO1990006515A1 (en) | 1988-12-09 | 1990-06-14 | Centocor, Inc. | Anti-idiotopic immunometric assay |
IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Luminescence test method and device based on magnetic tiny particles, containing many magnets |
ATE225801T1 (de) | 1992-07-13 | 2002-10-15 | Bionebraska Inc | Verfahren zur modifizierung rekombinanter polypeptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
PL218883B1 (pl) | 2000-02-24 | 2015-02-27 | Lilly Co Eli | Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
WO2004092197A2 (en) | 2003-04-07 | 2004-10-28 | The Regents Of The University Of California | Amyloid-specific peptides and uses thereof |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
EP1680666A4 (en) | 2003-10-27 | 2008-03-26 | Monogram Biosciences Inc | ANTI-THERAPEUTIC HUMAN ANTIBODY DETECTION |
US7763249B2 (en) | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
EP1838854B1 (en) | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antibodies that recognize Beta Amyloid Peptide |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
KR101047207B1 (ko) | 2006-03-09 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | 항-약물 항체 분석 |
EP1917854A1 (en) | 2006-11-06 | 2008-05-07 | F. Hoffmann-La Roche Ag | Method for producing anti idiotypic antibodies |
US20080127359A1 (en) * | 2006-11-06 | 2008-05-29 | Hermann Beck | Method for producing anti-idiotypic antibodies |
TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
-
2009
- 2009-12-15 US US12/637,833 patent/US8614297B2/en active Active
- 2009-12-18 KR KR1020137019063A patent/KR101777899B1/ko active IP Right Grant
- 2009-12-18 AU AU2009331900A patent/AU2009331900A1/en not_active Abandoned
- 2009-12-18 WO PCT/EP2009/009160 patent/WO2010072384A1/en active Application Filing
- 2009-12-18 JP JP2011542710A patent/JP5642702B2/ja active Active
- 2009-12-18 MX MX2011006641A patent/MX2011006641A/es active IP Right Grant
- 2009-12-18 LT LTEP09796629.5T patent/LT2379601T/lt unknown
- 2009-12-18 CA CA2746779A patent/CA2746779C/en active Active
- 2009-12-18 HU HUE09796629A patent/HUE030478T2/en unknown
- 2009-12-18 CN CN2009801517154A patent/CN102257010A/zh active Pending
- 2009-12-18 BR BRPI0923544-2A patent/BRPI0923544B1/pt not_active IP Right Cessation
- 2009-12-18 DK DK09796629.5T patent/DK2379601T3/en active
- 2009-12-18 KR KR1020117014278A patent/KR20110086182A/ko active Application Filing
- 2009-12-18 PL PL09796629T patent/PL2379601T3/pl unknown
- 2009-12-18 ES ES09796629.5T patent/ES2595981T3/es active Active
- 2009-12-18 SI SI200931544A patent/SI2379601T1/sl unknown
- 2009-12-18 PT PT97966295T patent/PT2379601T/pt unknown
- 2009-12-18 EP EP09796629.5A patent/EP2379601B1/en active Active
- 2009-12-18 MX MX2014009062A patent/MX352117B/es unknown
- 2009-12-18 CN CN201710026240.2A patent/CN106990251B/zh active Active
- 2009-12-21 AR ARP090104999A patent/AR074816A1/es unknown
- 2009-12-21 TW TW098143984A patent/TWI424162B/zh not_active IP Right Cessation
-
2011
- 2011-06-02 IL IL213343A patent/IL213343A0/en unknown
-
2013
- 2013-08-07 US US13/960,893 patent/US9547010B2/en active Active
-
2016
- 2016-10-25 HR HRP20161398TT patent/HRP20161398T1/hr unknown
- 2016-11-04 CY CY20161101134T patent/CY1118420T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0923544A2 (pt) | anticorpo anti-idiótipos contra um anticorpo contra o peptídeo beta amiloide | |
CR10556A (es) | Humanized antibody against amyloid beta | |
DK2177536T3 (da) | Antistoffer mod amyloid-beta-peptid | |
SMT201500186B (it) | Autoanticorpi umani anti-alfa-sinucleina | |
BRPI0917148A2 (pt) | anticorpos anti-cd5 | |
ATE543405T1 (de) | Frisiergerät | |
BRPI0720218A2 (pt) | Anticorpos monoclonais contra angptl3 | |
BRPI0923359A2 (pt) | Anticorpos anti-igf | |
BRPI0907577A2 (pt) | Moduladores para amiloide beta | |
DK3354267T3 (da) | Stabiliseret sulforaphan | |
BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
DK3118220T3 (da) | Protein | |
BRPI0814971A2 (pt) | Proteína | |
BRPI0915367A2 (pt) | peptídeos e epítopos anti-p2x7 | |
DK1895071T3 (da) | Markise uden vridning | |
BRPI0814127A2 (pt) | Polipeptídeos imunegênicos e anticorpos monoclonais | |
BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
BRPI1011805A2 (pt) | anticorpos anti incisura-1 | |
EP2348042A4 (en) | AMYLOID PEPTIDE BETA MODIFIED | |
BRPI0912769A2 (pt) | anticorpos anti-pirb | |
FI20075777A (fi) | Kate-elementti | |
BRPI0920651A2 (pt) | moduladores para amiloide beta | |
DE502008001751D1 (de) | Korrektor | |
DK2136192T3 (da) | Føler-fastgørelsesindretning | |
DK2046833T3 (da) | Humaniseret antistof mod amyloid beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |